Evaro, the NHS-licensed digital healthcare platform serving over 2 million patients, today announced it has closed £18.3 million in a Series A funding round led by AlbionVC, with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI. The platform embeds regulated prescription services directly into consumer brands, healthcare organisations, and employer benefit platforms. The funding will accelerate Evaro’s healthcare-as-a-service model across these three markets.
The round comes as 20.5 million people experienced month-long waits for a GP appointment in 2024, up 60% in seven years. Evaro provides regulated healthcare infrastructure that includes asynchronous consultations, remote diagnostics, prescribing, dispensing, and aftercare, which can be embedded into existing platforms within days. For partners, this creates new revenue streams with minimal implementation burden, while offering patients faster and more discreet access to care.
Founded in 2018 by emergency physician Dr. Thuria Wenbar and pharmacist researcher Dr. Oskar Wenbar, Evaro will use the funding to expand across treatment areas including women’s health, men’s health, and longevity medicine, develop advanced diagnostics and aftercare, and continue building its API-first platform infrastructure. The company holds CQC and GPhC licences, seven active regulatory approvals, and NHS integration enabling GP record access for safer prescribing.
When a third of people are waiting over a week just to see their GP, it’s time to think through alternative solutions that help people get the care they need while supporting NHS capacity. What we’ve built is infrastructure that allows our partners - brands people already trust - to deliver safe and regulated healthcare for common conditions without having to build a thing. We’re making healthcare as accessible as online banking, and this funding lets us prove that model works at scale.
Thuria Wenbar, Co-founder & CEO
We’ve seen embedded finance transform banking, Evaro is now driving the embedded health revolution. What sets Evaro apart is the depth of their regulatory stack. Evaro has spent seven years building its infrastructure properly, with deep regulatory credentials. This now allows consumer brands to enter the healthcare space safely, unlocking massive latent demand while relieving pressure on the NHS. We are thrilled to back the team as they define this new category.
Christoph Ruedig, Partner at AlbionVC
Patients now expect the same convenience from healthcare that they get from banking or shopping-instant, mobile, on their terms. The technology exists to deliver this for minor conditions, but our system is still stuck requiring appointments, phone calls, physical visits - with no capacity for smart aftercare. We want to solve this, and scale the infrastructure that matches how people actually want to access care in 2026.
Oskar Wenbar, Co-founder & Chief Medical Officer
